ScreenerHero

ZLAB Zai Lab Limited

NAS · US · Healthcare · Biotechnology · zailaboratory.com
25.31USD-1.06%Mkt Cap: 2.84B $P/E: —

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.84B USD
Enterprise Value2.51B USD
Revenue (TTM)449.61M USD
Gross Profit269.07M USD
Net Income (TTM)-175.54M USD
Revenue/Share4.06 USD
Last Price25.31 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.8K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.12
PEG—
EV/EBITDA-10.11
EV/Revenue5.58
P/S6.39
P/B4.73
EPS (TTM)-1.70
EPS (Forward)-2.11
52W Range
15.9650% of range34.72
52W High34.72 USD
52W Low15.96 USD
Profitability
Gross Margin58.47%
Oper. Margin-71.95%
EBITDA Margin-55.20%
Profit Margin-38.15%
ROE-24.53%
ROA-14.97%
Growth
Revenue Growth-3.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-150.79M USD
CapEx (TTM)13.42M USD
FCF Margin-18.67%
FCF Yield-2.95%
Net Debt-362.95M USD
Net Debt/EBITDA1.46
Balance Sheet
Debt/Equity0.31
Current Ratio2.13
Quick Ratio1.61
Book Value/Sh5.41 USD
Cash/Share5.50 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.14 USD
Upside (mean)+30.9%
Target Range24.25 USD – 50.00 USD
24.25+30.9% to mean50.00
# Analysts12
Ownership
Shares Out.112.27M
Float97.11M
Insiders2.12%
Institutions38.46%
Short Interest
Short Ratio8.1d
Short % Float7.41%
Short % Out.7.27%
Shares Short8.16M
Short (prev mo.)7.47M
Technical
SMA 5024.34 (+4.0%)
SMA 20020.44 (+23.8%)
Beta0.72
S&P 52W Chg15.78%
Avg Vol (30d)916.05K
Avg Vol (10d)722.03K
Technical Indicators
RSI (14)51.4
MACD0.3182
MACD Signal0.4784
MACD Hist.-0.1602
BB Upper26.81 USD
BB Middle25.38 USD
BB Lower23.94 USD
BB Width11.31%
ATR (14)1.136 USD
Vol Ratio (20d)0.35x